Navigation Links
At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizer's Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
Date:4/24/2013

EXTON, Pa., April 24 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. rheumatologists believe that—at three months post launch—initiations of Pfizer's Xeljanz in the rheumatoid arthritis (RA) treatment algorithm will follow methotrexate failure/intolerance and at least two biologic failures. Only one in ten surveyed physicians currently plan to use the treatment prior to biologic initiation.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

According to the BioTrends Research Group report entitled LaunchTrends®: Xeljanz, Wave 2, surveyed rheumatologists report that among their patients currently treated with Xeljanz, 87 percent were switched from a biologic agent, while the remaining 13 percent of current Xeljanz patients were biologic naive prior to initiation. When questioned directly about agents at risk for displacement, nearly one-quarter of rheumatologists believe that Xeljanz is most likely to displace Genentech's Actemra with regard to RA patient share.

The recently published report also reveals that at three months post launch, approximately one-third of surveyed rheumatologists report prescribing Xeljanz in an average of three RA patients. Although rheumatologists anticipate Xeljanz trial rates to increase in the future, four percent claim that they will never use Xeljanz, primarily due to efficacy concerns and side effects.

"The percent of rheumatologists who have used Xeljanz in at least one patient has remained around one-third since the first wave of research, at one-month post launch," said BioTrends Research Group Associate Director of Immunology '/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. deCODE Genetics, in Collaboration with Academic Colleagues, Discovers Three Variants in the Sequence of the Human Genome that Affect the Risk of Thyroid Cancer
2. Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
3. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
4. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
5. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
6. Three Hertz Foundation Fellows Receive Presidential Honors; Leaders in Applied Physical, Biological and Engineering Sciences
7. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
8. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
9. Alpha Source, Inc. Makes Third Straight Inc. 5000 List with Three-Year Sales Growth of 53%
10. Three Blockbuster Patent Cases at the Supreme Court This Term
11. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), ... announced that the U.S. Food and Drug Administration ... and Phase I clinical trials of the DPX-Anthrax ... co-development agreement signed with Gilead Life Sciences. The ... the DPX-Survivac. , “We have been in talks ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 FamilyFarms Group ... General Manager of State Line Farms, received the 2015 ... a producer, under the age of 35, who has ... is an honor to win the Tomorrow's Top Producer ... who won the Top Producer Award and learning from ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital IQ ... Stock Report coverage on MabVax Therapeutics Holdings Inc . ... a clinical stage biotechnology company focused on the development ... needs in the treatment of cancer. MabVax has discovered ... the protective immune responses generated by patients who have ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG), a clinical-stage ... affordable vaccines based on proprietary manufacturing technologies and ... included in a report of President Obama,s Council ... to the President on Reengineering the Influenza Vaccine ...
... Inc. (Nasdaq: ONTY ) today announced ... Financial Officer and Vice President, Corporate Development, effective ... financial management, investor relations and business development. ... of financial management experience to Oncothyreon," said Robert ...
... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington have designed ... conveniently compelled to release the ions in the presence of ... American Chemical Society today (online), IU Bloomington chemist Amar ... the molecule, how it works and, just as importantly, how ...
Cached Biology Technology:Medicago named in Presidential report on meeting the challenges of pandemic influenza 2Medicago named in Presidential report on meeting the challenges of pandemic influenza 3Medicago named in Presidential report on meeting the challenges of pandemic influenza 4ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER 2IU chemists develop new 'light switch' chloride binder 2IU chemists develop new 'light switch' chloride binder 3
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Spanish . Fernando Rendo, biologist at the ... with the intention of completing the genealogical tree ... Country Autonomous Community (CAPVEAE) and Navarre. Concretely, he opted for ... (a kind of variation in the DNA sequence) that can ...
... of how farmers could protect themselves by growing a ... of BioScience , has highlighted economical steps that ... from global climate change, including a greater frequency of ... considered a policy priority for agriculture. The survey, by ...
... stimuli, such as the scent of your morning coffee or ... to the appropriate brain region for analysis. The coffee aroma ... the auditory cortex. That division of labor suggests that ... is mounting that brain regions can take over functions they ...
Cached Biology News:Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3MIT-- parts of brain can switch functions 2MIT-- parts of brain can switch functions 3MIT-- parts of brain can switch functions 4
... The high-performance triple quadrupole 1200L sets ... today's cost-conscious environment - incorporating the ... for all liquid chromatography analytical needs. ... interface and the Transmission Quadrupole Analyzer ...
C1-inhibitor (C1-INH)...
... Bio luciferase assay. Mo Bio Laboratories offers the ... you to certify your products ATP-Free with a ... deliver them to your customers in a timely ... 3.5 x 10-12 /l, which will allow you ...
Choriongonadotropin (human, hCG)...
Biology Products: